(People's Daily Health Client Gao Ruirui) "Special governance of oral implant prices, National Patent Medicine Alliance for Centralized Purchase, and Dental Implant Craft No. 1 document release..." The People's Daily Health Client found that since September, multiple medical insurance documents have been released to promote the implementation of medical insurance policies.
Special treatment of oral implant prices kicked off
On September 8, the National Medical Insurance Administration issued the "Notice on the Special Treatment of Oral Implant Medical Service Charges and Consumables Prices" . The "Notice" clearly states that medical insurance departments at all levels should focus on the medical service price of a single conventional dental implant as the focus, and implement overall regulation in accordance with the medical service price of "diagnosis and examination + implant implant + crown insertion". Currently, the third-level public medical institutions have completed the full process of implantation. The overall medical service price is generally higher than 4,500 yuan per capsule. Targeted measures should be taken to introduce it to a new range of no more than 4,500 yuan per capsule. The regulatory goals of public medical institutions below the third level are reduced accordingly in accordance with the local medical service grading pricing policy.
National Chinese Patent Drug Alliance Centralized Purchase Launched
On September 9, National Chinese Patent Drug Joint Procurement Office issued the "National Chinese Patent Drug Alliance Procurement Announcement (No. 1 of 2022)". The announcement shows that the joint procurement office is conducting centralized procurement of 16 Chinese patent medicines. All public medical institutions (including military medical institutions) in the alliance area should participate. Medical insurance designated social medical institutions and designated pharmacies are encouraged to participate in accordance with the relevant regulations of the alliance area. The procurement cycle is 2 years and can be extended depending on the situation. The procurement agreement is signed every year during the procurement cycle. If the procurement volume of the year is completed in advance during the procurement cycle, the excess of the selected enterprises will still supply at the selected price until the procurement cycle expires.
Medical Insurance Information Platform Payment Method Management Subsystem Monitoring Point Construction of the National Unified Medical Insurance Information Platform Payment Method Management Subsystem Monitoring Point" clearly stated that Handan City, Hebei Province, Shangrao City, Jiangxi Province, Dongying City, Shandong Province, Wuhan City, Hubei Province, Shaoyang City, Hunan Province, and Guangzhou City, Guangdong Province were the first monitoring points. Adopt the principle of fewer first and more, slow first and fast first, and rolling selection and stubborn advancement, and then push it out in full after the number of monitoring points reaches about 30.
At present, the national unified medical insurance information platform has been launched in 31 provinces, autonomous regions and municipalities, covering 400,000 designated medical institutions + 400,000 designated pharmacies, and has played an important role in the fields of off-site medical treatment settlement, payment method reform, intelligent medical insurance supervision, drug procurement, and medical price monitoring. After the notice is released, the National Health Insurance Administration will carry out the construction of monitoring points for the payment method management subsystem with the DRG/DIP functional module as the focus, further promote the reform of medical insurance payment for drugs and consumables, and the reform of medical insurance payment has accelerated its entry into the "fast lane".
343 drugs passed the medical insurance drug catalog
On September 17, the official website of the National Health Insurance Administration announced the "2022 National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance Drug Catalog Adjustment Passes Formal Review". According to the "Announcement", there are 198 Western medicines and Chinese patent medicines outside the catalog, 145 Western medicines and Chinese patent medicines inside the catalog, and a total of 343 drugs passed the formal review. Compared with the public list released on September 6, the final official list reduced a Western medicine - metronidine genus vaginal expansion thrombus.
Compared with 2021, the number of drugs declared in the medical insurance catalog this year and the number of drugs that have passed the preliminary review have increased, and the overall proportion has also increased significantly, and it fully reflects the adjustment of the national medical insurance catalog to key varieties such as innovative drugs, rare diseases, children's drugs, and new coronary pneumonia treatment drugs. is the first domestic oral drug Azvdin, Pfizer's oral drug Nematvir tablet/ritonavir tablet, as well as CAR-T product Reki Olensai Injection, spinal muscular atrophy (SMA) treatment drug Lispolan oral solution powder.
Dental Implant Collective Purchase Document No. 1 issued
On the evening of September 22, the Inter-Provincial Alliance Centralized Volume Procurement Office of the Oral Implant System Inter-Provincial Alliance issued the "Announcement on the Inter-Provincial Alliance Centralized Volume Procurement of Oral Implant System Inter-Provincial Alliance (No. 1)" through the official website of the Sichuan Provincial Medical Insurance Bureau, clarifying information on procurement varieties, enterprise qualifications, medical institution scope, procurement cycle, procurement rules and other information.
Oral implantation is an important way to repair teeth missing. With the improvement of living standards and the deepening of population aging, my country's demand for dental implants has shown rapid growth in double-digits. The release of Document No. 1 marks that the sky-high dental implant procurement has finally entered the substantial stage of progress from the investigation.
Industry insiders believe that this centralized procurement plays a price "anchor" through the public hospital press conference, gradually transmitting the effectiveness of the regulatory target to non-public medical institutions, thereby guiding non-public medical institutions to lower the high price level. In addition, many securities companies have released research reports pointing out that domestic brands have cost-effective advantages and the probability of winning bids is high. The promotion of centralized procurement policies will be conducive to the rapid increase in the number of domestic implant brands, and the import substitution process is expected to continue to evolve.
average price reduction of 84%. The country has taken a "good start"
On September 27, the national orthopedic spinal consumables centralized volume procurement bid opening conference was held, and the planned winning results were generated through online bid opening. On September 30, the results of the centralized volume procurement of orthopedic spinal consumables were announced. This procurement is the third batch of high-value medical consumables organized by the state after cardiac stent and artificial joint . According to the needs of cervical and thoracic lumbar surgery, this procurement covers five orthopaedic spine consumables, including cervical spine fixation fusion, thoracic lumbar fixation fusion, vertebrae , endoscopic inferior nucleus pulposectomy, and artificial intervertebral disc replacement, forming 14 product system categories. intends to purchase 1.09 million sets in the first year, accounting for 90% of the total demand for medical institutions nationwide, involving a market size of about 31 billion yuan. The average price reduction of this centralized procurement is 84%. Based on the agreed procurement volume, it is estimated that 26 billion yuan of expenses can be saved each year.
